Wells Fargo
VIR icon

Wells Fargo’s Vir Biotechnology VIR Stock Holding History

Wells Fargo’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
114,269
+72,708
+175% +$692K ﹤0.01% 3995
2026
Q1 		$372K Sell
41,561
-63,851
-61% -$509K ﹤0.01% 4314
2025
Q4 		$636K Buy
105,412
+29,967
+40% +$178K ﹤0.01% 4309
2025
Q3 		$431K Buy
75,445
+13,278
+21% +$67.9K ﹤0.01% 4410
2025
Q2 		$313K Buy
62,167
+5,735
+10% +$30.7K ﹤0.01% 4471
2025
Q1 		$366K Buy
56,432
+3,771
+7% +$33.5K ﹤0.01% 4294
2024
Q4 		$387K Sell
52,661
-199,096
-79% -$1.57M ﹤0.01% 4353
2024
Q3 		$1.89M Buy
251,757
+209,341
+494% +$1.82M ﹤0.01% 3095
2024
Q2 		$378K Buy
42,416
+12,620
+42% +$121K ﹤0.01% 4088
2024
Q1 		$302K Buy
29,796
+3,771
+14% +$38.4K ﹤0.01% 4217
2023
Q4 		$262K Sell
26,025
-90,443
-78% -$826K ﹤0.01% 4299
2023
Q3 		$1.09M Buy
116,468
+26,028
+29% +$371K ﹤0.01% 3267
2023
Q2 		$2.22M Buy
90,440
+20,313
+29% +$510K ﹤0.01% 2823
2023
Q1 		$1.63M Buy
70,127
+63,824
+1,013% +$1.63M ﹤0.01% 3033
2022
Q4 		$160K Sell
6,303
-5,060
-45% -$124K ﹤0.01% 4295
2022
Q3 		$219K Sell
11,363
-1,385
-11% -$35.2K ﹤0.01% 4195
2022
Q2 		$325K Sell
12,748
-29,471
-70% -$688K ﹤0.01% 4008
2022
Q1 		$1.09M Sell
42,219
-17,963
-30% -$533K ﹤0.01% 3815
2021
Q4 		$2.52M Sell
60,182
-377
-0.6% -$14.8K ﹤0.01% 3248
2021
Q3 		$2.63M Buy
60,559
+42,761
+240% +$1.85M ﹤0.01% 3435
2021
Q2 		$842K Sell
17,798
-4,711
-21% -$214K ﹤0.01% 4320
2021
Q1 		$1.15M Sell
22,509
-77,602
-78% -$4.18M ﹤0.01% 4149
2020
Q4 		$2.68M Buy
100,111
+58,771
+142% +$1.91M ﹤0.01% 3280
2020
Q3 		$1.42M Sell
41,340
-26,294
-39% -$1.13M ﹤0.01% 3598
2020
Q2 		$2.77M Buy
67,634
+55,674
+466% +$1.87M ﹤0.01% 3007
2020
Q1 		$410K Buy
11,960
+11,373
+1,937% +$306K ﹤0.01% 4187
2019
Q4 		$7K Buy
+587
New +$7.86K ﹤0.01% 5982

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wells Fargo's VIR Position: Q2 2026 in Review

Wells Fargo increased its Vir Biotechnology (VIR) stake by 175% in Q2 2026, buying an estimated $692K and bringing the position to 114,269 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3995.

Wells Fargo first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.77M in Q2 2020. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Wells Fargo held 114,269 shares of Vir Biotechnology worth $1.16M as of Q2 2026.
  • Wells Fargo bought 72,708 Vir Biotechnology shares in Q2 2026, an estimated $692K.
  • Vir Biotechnology made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3995 holding.
  • Wells Fargo first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Wells Fargo's Vir Biotechnology position peaked at $2.77M in Q2 2020.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.